Baldwin Wealth Partners LLC MA Sells 5,032 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Baldwin Wealth Partners LLC MA lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 63.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,961 shares of the medical instruments supplier's stock after selling 5,032 shares during the quarter. Baldwin Wealth Partners LLC MA's holdings in LeMaitre Vascular were worth $273,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. NBC Securities Inc. lifted its position in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 183 shares during the last quarter. USA Financial Formulas bought a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at approximately $60,000. GAMMA Investing LLC increased its position in LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock worth $68,000 after purchasing an additional 188 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in LeMaitre Vascular in the 2nd quarter valued at approximately $82,000. Finally, KBC Group NV grew its stake in shares of LeMaitre Vascular by 58.4% during the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after buying an additional 410 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $3.22 during trading on Friday, reaching $96.93. The stock had a trading volume of 189,647 shares, compared to its average volume of 140,622. LeMaitre Vascular, Inc. has a 52 week low of $56.61 and a 52 week high of $109.58. The firm's fifty day moving average is $97.75 and its 200 day moving average is $92.73. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of 52.97, a P/E/G ratio of 2.20 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. During the same period last year, the company posted $0.33 EPS. The business's quarterly revenue was up 15.6% on a year-over-year basis. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the firm's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 10.79% of the company's stock.

Analysts Set New Price Targets

LMAT has been the topic of several recent research reports. StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Barrington Research lifted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research note on Friday, November 1st. Cantor Fitzgerald began coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price objective for the company. Finally, Oppenheimer reiterated an "outperform" rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.